32 stories
Retatrutide is Eli Lilly's GLP-1/GIP/glucagon triple agonist, now the most efficacious obesity peptide ever read out in Phase 3. Phase 2 work showed mean weight loss above 24% at 48 weeks plus an 86% reduction in liver fat at 48 weeks, ahead of every approved drug.
TRIUMPH-1 topline released May 21, 2026 is the registrational readout that anchors the planned NDA. In 2,339 adults with obesity or overweight and at least one weight-related comorbidity without diabetes, retatrutide produced 28.3% mean weight loss at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg over 80 weeks versus 2.2% on placebo. 45.3% of participants on 12 mg reached ≥30% weight loss — bariatric-surgery territory. A 104-week extension in the BMI ≥35 subgroup pushed mean weight loss to 30.3% (85.0 lbs). Transient ALT elevations that surfaced in TRIUMPH-4 reappeared and normalized by week 24, consistent with hepatic triglyceride mobilization. Discontinuation rates ran 4.1%, 6.9%, and 11.3% across 4, 9, and 12 mg arms versus 4.9% placebo. TRIUMPH-4 in obesity with knee osteoarthritis posted 28.7% mean weight loss at 68 weeks plus 75.8% reduction in WOMAC pain. TRANSCEND T2D1 in type-2 diabetes reported A1c down 1.7 to 2.0 percentage points and 25 to 37 lb mean weight loss versus placebo. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established cardiovascular disease) read out later in 2026. The 10,000-patient TRIUMPH-OUTCOMES cardiovascular trial reads out 2027. Full TRIUMPH-1 data lands at ADA 2026 (June 5-8, New Orleans).
Retatrutide has also leaked into the unregulated research-peptide channel; the April 2026 Utah federal indictment of an osteopathic physician for selling 200+ patients misbranded Chinese peptides named retatrutide alongside semaglutide, tirzepatide, and BPC-157. Stories here cover the trial readouts, mechanism work, and the access fight.
Clarivate projects orforglipron and retatrutide as the defining GLP-1 drugs of the next decade. Retatrutide is projected for 2028 launch after seven additional Phase III readouts expected this year.
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
TikTok users on retatrutide report emotional blunting. Neuroscientist Paul Kenny of Mount Sinai says researchers are investigating whether GLP-1 drugs act as general reward dampeners affecting the brain's mesolimbic system.
Deep dive into the retatrutide hype cycle triggered by Andrew Huberman's endorsement and looksmaxxing influencers. Frames the triple-agonist as potentially more consequential than Ozempic.
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
Analyst deep-dive into Lilly's position as healthcare's most valuable company, with ~60% U.S. incretin market share driven by tirzepatide and a retatrutide pipeline showing ~30% weight loss potential.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.
Eli Lilly's triple-agonist achieved record weight loss at the highest dose with substantial reductions in knee osteoarthritis pain. Seven more Phase 3 trials expected in 2026.
Analysis of the TRIUMPH program (TRIUMPH-1 through TRIUMPH-4) published in Diabetes, Obesity, and Metabolism shows unprecedented average weight reduction of up to 24% across 5,800+ adults.